Lazertinib
Lazertinib[edit | edit source]
Lazertinib is a tyrosine kinase inhibitor (TKI) used in the treatment of certain types of non-small cell lung cancer (NSCLC). It specifically targets the epidermal growth factor receptor (EGFR) mutations that are often implicated in the development and progression of NSCLC. Lazertinib is designed to overcome resistance to earlier generations of EGFR inhibitors, particularly those that develop due to the T790M mutation.
Mechanism of Action[edit | edit source]
Lazertinib works by selectively inhibiting the activity of mutant forms of the EGFR, which are known to drive the growth of cancer cells in NSCLC. By binding to the ATP-binding site of the EGFR, lazertinib prevents the receptor from activating downstream signaling pathways that promote cell proliferation and survival. This inhibition is particularly effective against the T790M mutation, a common resistance mechanism to first- and second-generation EGFR inhibitors.
Clinical Use[edit | edit source]
Lazertinib is primarily used in patients with advanced or metastatic NSCLC who have specific EGFR mutations. It is often prescribed after the failure of first-line EGFR TKIs due to resistance mutations. The drug has shown efficacy in shrinking tumors and delaying disease progression in clinical trials.
Development and Approval[edit | edit source]
Lazertinib was developed by Yuhan Corporation, a South Korean pharmaceutical company. It has undergone various phases of clinical trials to establish its safety and efficacy. The drug has been approved for use in several countries, with ongoing studies to further explore its potential in combination therapies and in earlier lines of treatment.
Side Effects[edit | edit source]
Common side effects of lazertinib include rash, diarrhea, and fatigue. These are generally manageable with supportive care. More serious adverse effects can include interstitial lung disease and liver enzyme abnormalities, which require careful monitoring and management.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
